Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 43.0 Cr.
- Current Price ₹ 45.8
- High / Low ₹ 53.3 / 37.8
- Stock P/E 18.5
- Book Value ₹ 17.6
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 15.1 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 57.9 days to 42.2 days
Cons
- Stock is trading at 2.59 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.2% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
6.07 | 26.76 | 35.14 | 62.52 | 71.76 | |
5.61 | 25.74 | 31.65 | 57.77 | 66.04 | |
Operating Profit | 0.46 | 1.02 | 3.49 | 4.75 | 5.72 |
OPM % | 7.58% | 3.81% | 9.93% | 7.60% | 7.97% |
0.00 | 0.02 | 0.32 | 0.22 | 0.27 | |
Interest | 0.18 | 0.48 | 0.79 | 0.67 | 0.29 |
Depreciation | 0.12 | 0.28 | 1.91 | 1.81 | 1.82 |
Profit before tax | 0.16 | 0.28 | 1.11 | 2.49 | 3.88 |
Tax % | 6.25% | -32.14% | 27.03% | 22.09% | 27.84% |
0.15 | 0.36 | 0.81 | 1.94 | 2.79 | |
EPS in Rs | 0.22 | 0.42 | 0.65 | 1.68 | 2.47 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 39% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 81% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 |
Reserves | 1.44 | 6.45 | 7.17 | 9.49 | 7.17 |
7.49 | 7.25 | 10.30 | 8.30 | 7.85 | |
5.73 | 9.85 | 12.29 | 14.67 | 22.98 | |
Total Liabilities | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 |
1.70 | 2.01 | 10.13 | 10.20 | 10.65 | |
CWIP | 1.22 | 4.48 | 0.02 | 0.02 | 0.03 |
Investments | 0.00 | 0.49 | 0.02 | 1.88 | 1.88 |
15.08 | 21.11 | 24.13 | 25.06 | 34.83 | |
Total Assets | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-0.31 | -1.08 | 1.10 | 5.35 | 4.06 | |
-2.02 | -6.14 | -3.44 | -3.61 | -2.30 | |
2.95 | 6.71 | 2.42 | -1.77 | -0.68 | |
Net Cash Flow | 0.62 | -0.51 | 0.07 | -0.03 | 1.08 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 430.54 | 124.26 | 129.63 | 78.46 | 107.73 |
Inventory Days | 369.26 | 103.22 | 128.73 | 67.15 | 67.85 |
Days Payable | 455.40 | 135.07 | 143.88 | 72.94 | 108.50 |
Cash Conversion Cycle | 344.41 | 92.41 | 114.48 | 72.67 | 67.07 |
Working Capital Days | 316.29 | 61.65 | 87.87 | 43.55 | 42.17 |
ROCE % | 4.85% | 8.78% | 12.75% | 16.08% |
Documents
Announcements
-
Structural Digital Database
18 October 2025 - SDD compliance certificate for quarter ended 30 Sep 2025; captured 2 events; no non-compliance (Walpar Nutritions).
-
Structural Digital Database
10 October 2025 - SDD compliance certificate for quarter ended 30 Sep 2025; captured two events; no non-compliance.
-
Updates
10 October 2025 - Walpar Nutritions: corporate governance provisions not applicable for quarter ended 30 Sep 2025 (SME exchange listing).
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
10 October 2025 - RTA certifies no physical share certificates received for dematerialization for quarter ended 30 September 2025.
-
Trading Window
30 September 2025 - Trading window closed from 1 Oct 2025 until 48 hours after Q2/H1 unaudited results publication.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products